SYNRIBO® Approved for use in Chronic Myeloid Leukemia

Posted on February 21st, 2014 by

The U.S. Food and Drug Administration (FDA) has granted full approval of SYNRIBO® (omacetaxine mepesuccinate) for injection. SYNRIBO is indicated for adult patients with chronic phase (CP +0.28%, news) or accelerated phase (AP) chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs).  SYNRIBO® is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).

The original approval of SYNRIBO® was based on an analysis of combined data subsets from two Phase 2, open-label, multicenter studies. The pooled analysis included patients who had received 2 or more approved TKIs and, at a minimum, had evidence of resistance or intolerance to dasatinib and/or nilotinib. 47% of CP patients and 63% of AP patients had failed treatment with imatinib, dasatinib, and nilotinib. The majority of patients had also received other treatments including hydroxyurea, interferon, and cytarabine.

  • For CP patients, 18% (14/76) achieved a major cytogenetic response (MCyR) with a mean time to MCyR onset of 3.5 months. The median duration of MCyR for these patients was 12.5 months (Kaplan-Meier estimate).
  • For AP Patients, 14% (5/35) achieved a major hematologic response (MaHR) with a mean time to response onset of 2.3 months. The median duration of MaHR for these patients was 4.7 months (Kaplan-Meier estimate).
  • Most common adverse reactions (frequency ?20%) in chronic and accelerated phase patients: thrombocytopenia, anemia, neutropenia, diarrhea, nausea, fatigue, asthenia, injection site reaction, pyrexia, infection, and lymphopenia

About OMNI Health Media: OMNI Health Media is a leading specialty publisher of health-related information with an emphasis on cancer, and on line applications and websites specifically for consumers. Established in 1996, OMNI develops and distributes multi-media health education content and programming, with an emphasis on cancer and women’s health. OMNI has developed over 200 websites and supplies educational content and programming to over 2700 physicians for use on cancer center and clinic websites, including CancerConnect.com. OMNI’s award-wining content programs reach over 1 million seekers of cancer information in English, Japanese, and Spanish each month. http://omnihealthmedia.com

Copyright © 2014 CancerConsultants. All Rights Reserved.

Tags: Chronic Myeloid Leukemia, Leukemia, News

You must be logged-in to the site to post a comment.